← Back
Treatment and the treatment process

Treatment of CLL

Chronic lymphocytic leukemia (CLL) often develops slowly. This topic explains when treatment starts and the modern options.

Last updated: ~2 min read
On a dark navy background, an hourglass holding calm small spheres instead of sand.
Figure 1.In early CLL, active monitoring is a proven approach.

01Short answer

For many people, CLL stays without symptoms for years and needs no treatment; during this time "active monitoring" (watch and wait) with regular check-ups is used. Treatment starts when the disease becomes active: severe tiredness, fever, night sweats, weight loss, growing lymph nodes or spleen, or falling blood counts (iwCLL criteria). Modern treatment is built on targeted drugs: BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib, and pirtobrutinib at relapse) are usually taken continuously; the BCL-2 inhibitor venetoclax is given with an anti-CD20 antibody (obinutuzumab) or with ibrutinib for a fixed time (12–15 months). Chemoimmunotherapy is now used less. TP53 and IGHV tests influence the choice.

02Simple explanation

Waiting is also a plan. Early CLL is often just monitored.

When does treatment start? When symptoms appear or blood counts worsen.

Tablets. Most modern treatments are taken by mouth.

Infection protection. CLL weakens immunity; vaccines matter.

03Scientific explanation

Stages: the Rai and Binet systems assess lymph nodes, spleen, haemoglobin and platelets. The CLL-IPI risk index combines TP53, IGHV, β2-microglobulin, age and stage.

Targeted therapy: BTK inhibitors block B-cell receptor signalling; venetoclax blocks the BCL-2 protein and restores programmed cell death. At the start of venetoclax the dose is increased gradually and blood tests are monitored to prevent tumour lysis syndrome.

High risk: with del(17p)/TP53 mutation, chemoimmunotherapy works poorly and targeted drugs are preferred. At relapse, CAR-T and allogeneic transplant are considered for selected people.

04What happens in the body?

Active monitoring

The doctor usually does blood tests and an examination every 3–12 months. Normal life continues meanwhile. Some people never need treatment.

Treatment options

Continuous BTK inhibitor treatment or a fixed-duration venetoclax-based regimen — both are effective. The choice considers heart rhythm, bleeding risk, kidney function, other medicines and personal preference.

Inside a translucent lymphocyte, two glowing targets: near the membrane and on the mitochondria.
Figure 2.BTK and BCL-2 are the two main targets in CLL.

After treatment

Lymph nodes shrink and blood counts improve. Infection protection, vaccines (except live vaccines) and skin cancer checks are part of long-term care.

On a translucent silhouette, lymph nodes at the neck, armpits and groin gradually dim.
Figure 3.With treatment, lymph nodes shrink.

05The decision path in CLL

A simplified outline.

Monitoring — Regular tests.1MonitoringRegular tests.
Tests — TP53, IGHV.2TestsTP53, IGHV.
Treatment — BTK or venetoclax.3TreatmentBTK or venetoclax.
Protection — Infections and vaccines.4ProtectionInfections and vaccines.
ControlDisease quiet.
Personal choiceBy genetics.
Shared decisionWith your preferences.

06Main treatment options in CLL

OptionHow givenNote
Active monitoringRegular checksEarly CLL without symptoms
BTK inhibitorsDaily tablet, continuousHeart rhythm, bleeding, blood pressure monitored
Venetoclax + obinutuzumabAbout 12 monthsTumour lysis monitoring
Venetoclax + ibrutinibFixed durationIn some countries
ChemoimmunotherapyIn coursesNow rarely; selected cases
CAR-T / transplantAt relapseSelected people

* Availability varies by country; your doctor makes the choice.

07Key terms

Active monitoring
Regular checks without treatment.
BTK
An enzyme in B-cell signalling.
BCL-2
A protein that prevents cell death.
IGHV
An immunoglobulin gene that affects risk.
TP53
A gene indicating high risk.
Tumour lysis syndrome
Changes in blood salts when cells break down fast.

08Key points

  • Early CLL is often monitored.
  • Treatment starts by set criteria.
  • Targeted drugs are the main choice.
  • TP53 and IGHV shape the choice.
  • Protection from infection matters.
  • Plan vaccines with your doctor.

09Frequently asked questions

Why wait instead of treating?

Early treatment of CLL without symptoms does not extend life but does cause side effects.

How long do I take a BTK inhibitor?

Usually for as long as it works and is tolerated.

Can CLL be cured?

It is usually seen as a chronic disease controlled for many years.

Should I have a flu vaccine?

Usually recommended; live vaccines are avoided — ask your doctor.

10Questions for your doctor

Take these questions to your appointment. The ones you save are collected on the “My questions” page and stay on this device only.

  1. Why wait instead of treating?

  2. How long do I take a BTK inhibitor?

  3. Can CLL be cured?

  4. Should I have a flu vaccine?

My questions

12Sources

  1. National Cancer Institute (NCI). Chronic Lymphocytic Leukemia Treatment (PDQ) – Patient Version
  2. American Cancer Society. Treating Chronic Lymphocytic Leukemia
  3. Cancer Research UK. Treatment for chronic lymphocytic leukaemia (CLL)
  4. NHS. Chronic lymphocytic leukaemia: Treatment
  5. Cancer Research UK. Treatment for chronic lymphocytic leukaemia (CLL)
  6. ESMO. ESMO Clinical Practice Guidelines: Haematological Malignancies
  7. American Cancer Society. Immunotherapy for CLL
  8. Cancer Research UK. CAR T-cell therapy
  9. Biology of Blood and Marrow Transplantation, 2019. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
  10. American Cancer Society. Stem Cell or Bone Marrow Transplant
Medical disclaimerThis information is for educational purposes only and does not replace medical advice.
Last updated: ← Back to the list

Open the interactive site →